Open Access

BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer

  • Authors:
    • Tatsuya Morikawa
    • Ryo Inada
    • Takeshi Nagasaka
    • Yoshiko Mori
    • Hiroyuki Kishimoto
    • Takashi Kawai
    • Yuzo Umeda
    • Hideyuki Mishima
    • Ajay Goel
    • Toshiyoshi Fujiwara
  • View Affiliations

  • Published online on: December 8, 2017     https://doi.org/10.3892/ol.2017.7553
  • Pages: 2195-2201
  • Copyright: © Morikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

In stage IV colorectal cancer (CRC), initial resection of the primary tumor is considered to be an important strategy for improving disease outcome. However, there is no consensus on the timing as to when the surgical intervention of the primary tumor should occur. The present study hypothesizes that genetic profiles in CRC may indicate the appropriate treatment strategies for patients with stage IV CRC, and a cohort of 113 patients with stage IV CRC resected primary lesions at various periods were analyzed for the presence of mutations in the KRAS, exon 2, and BRAF genes, exon 15, and for the microsatellite instability status of the tumor. These data were additionally correlated with various clinicopathological features. Although BRAF‑mutant was revealed to be an independent negative prognostic factor in stage IV CRC (HR, 8.42; 95% confidence interval, 2.72‑26.02), BRAF‑mutant samples exhibited better prognoses if they were treated with chemotherapy prior to tumor resection. Thus, the presence of BRAF mutations provides a compelling rationale for the establishment of intensive upfront chemotherapy to improve survival in stage IV CRC.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Morikawa, T., Inada, R., Nagasaka, T., Mori, Y., Kishimoto, H., Kawai, T. ... Fujiwara, T. (2018). BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncology Letters, 15, 2195-2201. https://doi.org/10.3892/ol.2017.7553
MLA
Morikawa, T., Inada, R., Nagasaka, T., Mori, Y., Kishimoto, H., Kawai, T., Umeda, Y., Mishima, H., Goel, A., Fujiwara, T."BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer". Oncology Letters 15.2 (2018): 2195-2201.
Chicago
Morikawa, T., Inada, R., Nagasaka, T., Mori, Y., Kishimoto, H., Kawai, T., Umeda, Y., Mishima, H., Goel, A., Fujiwara, T."BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer". Oncology Letters 15, no. 2 (2018): 2195-2201. https://doi.org/10.3892/ol.2017.7553